Capabilities by Region
Greenhill is active in all major markets with meaningful corporate advisory activity, including in North America, Europe, Asia, and Australia.
Recent Transactions
Sort By
IAC/InterActiveCorp
Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the potential creation of a new class of non-voting common stock
Save-A-Lot
Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the US, on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Texas Competitive Electric Holdings and its subsidiaries
Advised Texas Competitive Electric Holdings, Texas’ largest power generator and competitive retail electricity provider, and its subsidiaries at the direction of its independent director in connection with its and Energy Future Holdings’ Chapter 11 proceedings
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
van Gansewinkel Groep BV
Advised Shanks Group plc, a leading international waste to product business, on the proposed merger with van Gansewinkel Groep BV, one of the leading waste management service providers, recyclers and suppliers of high-quality secondary raw materials in the Benelux region.
TEGNA, Inc.
Advised TEGNA, Inc., a major broadcasting and digital marketing services company, on the spin-off of Cars.com and the creation of two independent publicly traded companies: one focused on television broadcasting and one focused on the online automotive marketplace.
Valves & Controls Business of Pentair
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
Whistler Blackcomb Holdings Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
Aquasana, Inc.
Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton
BioD, LLC
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
New Enterprise Stone & Lime Co., Inc.
Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
ReachLocal
Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
Dobbies Garden Centres
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Aegerion Pharmaceuticals
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Giraffe restaurants
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan